The condition of the hepatobiliary system in children with cystic fibrosis

Abstract

Presented was an overview of domestic and foreign literature on the condition of the hepatobiliary system in children with cystic fibrosis. Due to an increasing life expectancy of cystic fibrosis patients in the last decade, the frequency of complications from the hepatobiliary system (cholestatic hepatitis, portal hypertension, liver cirrhosis), which, according to various authors, range from 20 to 80%, also increases. The most pronounced changes in the liver and the gall bladder are characteristic for children with moderate pulmonary symptoms and predominantly with the intestinal form of the disease. The risk factors for liver damage in cystic fibrosis are - pancreatic insufficiency, «severe» mutation, male sex, meconium ileus in the past medical history and earlier age at which the disease was diagnosed. Complex ultrasound assessment of the liver parenchyma and blood flow in the portal vascular system and in the celiac trunk make it possible to specify the severity of fibrosis and to identify early signs of portal hypertension. Magnetic resonance imaging can confirm the presence of liver cirrhosis and determine collateral circulation associated with portal hypertension. Magnetic resonance cholangiography and radionuclide imaging make it possible to determine the status of intra- and extrahepatic biliary system. There is currently no effective treatment that could prevent the progression of liver damage. There are reports of the beneficial effects of ursodeoxycholic acid drugs. Perspective directions of treatment - liver transplantation and genetic engineering. Methods of conservative, endoscopic and surgical treatment of bleeding esophageal varices are used during the portal hypertension syndrome.

Keywords

cystic fibrosis / hepatobiliary system / ultrasound diagnosis / ursodeoxycholic acid

References

[1] Амелина Е.Л., Черняк А.В. Муковисцидоз: определение продолжительности жизни // Пульмонология. - 2001. - №11 - С. 61-64.

[2] Дворяковский И.В., Симонова О.И., Дворяковская Г.М. Новые возможности ультразвуковых исследований органов брюшной полости при муковисцидозе у детей // Росс. педиатр. ж. - 2008. - №4. - С. 33-37.

[3] Делягин В.М., Капранов Н.И., Каширская Н.Ю. Лучевая диагностика поражений печени, жёлчного пузыря и поджелудочной железы при муковисцидозе у детей // SonoAce Internat. - 2003. - №11. - С. 48-53.

[4] Кан В.К. Диагностика и лечение больных с синдромом холестаза // Русс. мед. ж. - 2004. - №3 - С. 5-8.

[5] Капранов Н.И. Муковисцидоз. Современное состояние проблемы // Пульмонология. - 2006 (приложение). - С. 5-11.

[6] Капустина Т.Ю., Каширская Н.Ю., Неудахин Е.В. Длительное применение урсодезоксихолевой кислоты при поражении печени у больных муковисцидозом // Росс. гастроэнтерол. ж. - 2000. - №2. - С. 61-67.

[7] Капустина Т.Ю., Каширская Н.Ю., Капранов Н.И. Состояние гепатобилиарной системы у детей, больных муковисцидозом // Пульмонология. - 2006 (приложение). - С. 22-24.

[8] Рейзис А.Р., Никитина Т.С. Поддерживающая патогенетическая терапия поражения печени и желчевыводящих путей у детей и подростков с вирусными гепатитами, протекающими на фоне различной соматической патологии // Росс. ж. гастроэнтерол., гепатол., колопроктол. - 2004. - №1. - С. 45-48.

[9] Сологуб Т.С., Суборова Т.Н., Гембицкая Т.Е. Сравнительная активность антибиотиков в отношении Ps. aeruginosa - ведущего возбудителя респираторной инфекции у больных муковисицидозом и пациентов отделения реанимации и интенсивной терапии // Пульмонология. - 2006 (приложение) - С. 64-67.

[10] Behrman R.E., Kliegman R.M., Jenson H.B. Cystic fibrosis / Nelson textbook of pediatrics. 17th ed. - Philadelphia, P. Saunders, 2004. - Р. 1437-1450.

[11] Bush A. Cystic fibrosis in the 21-st century // Basel. Karger. - 2006. - Vol. 34. - P. 251-261.

[12] Chen A.H., Innis S.M., Davidson G.F. Phosphatidylcholine and lysophosphatidyl-choline excretion is increased in children with cystic fibrosis and is associated with plasma homocysteine, S-adenosylhomocysteine, and S-adenosylmethionine // Am. J. Clin. Nutr. - 2005. - Vol. 81. - P. 686-691.

[13] Colombo C. Liver disease in cystic fibrosis // Curr. Opin. Pulm. Med. - 2007. - Vol. 13. - P. 529-536.

[14] Corbett K., Kelleher S., Rowland M. Cystic fibrosis-associated liver disease: a population-based study // J. Pediatr. - 2004. - Vol. 145. - P. 327-332.

[15] Akata D, Akhan O. Liver manifestations of cystic fibrosis // Eur. J. Radiol. - 2007. - Vol. 61. - P. 11-17.

[16] Efrati O., Barak A. Liver cirrhosis and portal hypertension in cystic fibrosis // Eur. J. Gastroenterol. Hepatol. - 2003. - Vol. 15. - P. 1073-1078.

[17] Fustik S., Trajkovska M., Jakovska T. Screening for liver disease in cystic fibrosis: analysis of clinical and genetic risk factors for its development // Turk. J. Pediatr. - 2008. - Vol. 50. - P. 526-532.

[18] Henrion-Caude A., Flamant C., Roussey M. Liver disease in pediatric patients with cystic fibrosis is associated with glutathione S-transferase P1 polymorphism // Hepatology. - 2002. - Vol. 36. - P. 913-917.

[19] Hodson M.E., Duncan M.G. Cystic fibrosis. - London: Chapman & Hall, 1995. - P. 281-292.

[20] Lamireau T., Monnereau S., Martin S. Epidemiology of liver disease in cystic fibrosis: a longitudinal study // J. Hepatol. - 2004. - Vol. 41. - P. 920-925.

[21] Manns M.P., Boye J.L., Jansen P.M. Cholestatic liver diseases. - Dordrecht: Kluwer Academic Publishers, 1998. - Р. 356.

[22] O’Brien S., Keogan M., Casey M. Biliary complications of cystic fibrosis // Gut. - 1992. - Vol. 33. - P. 387-391.

[23] Ratjen F., Doring G. Cystic fibrosis // Lancet. - 2003. - Vol. 361. - P. 681-689.

[24] Salvatore F., Scudiero O., Castalso G. Genotype-phenotype correlation in cystic fibrosis: The role of modifier genes // Am. J. Med. Genet. - 2002. - Vol. 111. - P. 88-95.

[25] Stewart L. The role of abdominal ultrasound in the diagnosis, staging and management of cystic fibrosis liver disease // J. Royal Soc. Med. - 2005. - Vol. 98, suppl. 45. - P. 17-27.

RIGHTS & PERMISSIONS

Kondratieva O.V., Rylova N.V.